BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.48 Million USD | -19.9% |
| 2022 | -7.07 Million USD | -389.48% |
| 2021 | -1.44 Million USD | 39.5% |
| 2020 | -2.38 Million USD | 62.57% |
| 2019 | -6.38 Million USD | 15.95% |
| 2018 | -7.59 Million USD | -56.88% |
| 2017 | -4.84 Million USD | -35.89% |
| 2016 | -3.56 Million USD | -49.67% |
| 2015 | -2.38 Million USD | -1057.82% |
| 2014 | -205.59 Thousand USD | 53.46% |
| 2013 | -441.78 Thousand USD | 86.74% |
| 2012 | -3.33 Million USD | -532.15% |
| 2011 | -527.13 Thousand USD | -121.23% |
| 2010 | -238.27 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 4.44 Million USD | 262.03% |
| 2024 Q2 | 6.36 Million USD | 43.23% |
| 2023 FY | -8.48 Million USD | -19.9% |
| 2023 Q2 | -2.6 Million USD | -52.86% |
| 2023 Q4 | -2.74 Million USD | -846.37% |
| 2023 Q3 | 367.31 Thousand USD | 114.11% |
| 2023 Q1 | -1.7 Million USD | 52.74% |
| 2022 Q3 | -797.22 Thousand USD | -529.15% |
| 2022 FY | -7.07 Million USD | -389.48% |
| 2022 Q4 | -3.6 Million USD | -352.06% |
| 2022 Q1 | -2.88 Million USD | -735.4% |
| 2022 Q2 | 185.77 Thousand USD | 106.44% |
| 2021 FY | -1.44 Million USD | 39.5% |
| 2021 Q4 | -345.35 Thousand USD | 23.59% |
| 2021 Q1 | -358.79 Thousand USD | 38.0% |
| 2021 Q2 | -289.27 Thousand USD | 19.37% |
| 2021 Q3 | -451.96 Thousand USD | -56.24% |
| 2020 Q1 | -406.28 Thousand USD | 18.49% |
| 2020 Q3 | -716.39 Thousand USD | -4.16% |
| 2020 Q4 | -578.74 Thousand USD | 19.22% |
| 2020 FY | -2.38 Million USD | 62.57% |
| 2020 Q2 | -687.8 Thousand USD | -69.29% |
| 2019 Q1 | -2.38 Million USD | 0.0% |
| 2019 FY | -6.38 Million USD | 15.95% |
| 2019 Q4 | -498.45 Thousand USD | 63.95% |
| 2019 Q3 | -1.38 Million USD | 34.75% |
| 2019 Q2 | -2.11 Million USD | 11.08% |
| 2018 Q1 | -1.33 Million USD | -252.42% |
| 2018 FY | -7.59 Million USD | -56.88% |
| 2018 Q2 | -862.3 Thousand USD | 35.63% |
| 2017 Q3 | -1.58 Million USD | 2.28% |
| 2017 Q4 | -380.14 Thousand USD | 75.99% |
| 2017 FY | -4.84 Million USD | -35.89% |
| 2017 Q1 | -262.09 Thousand USD | -115.17% |
| 2017 Q2 | -1.62 Million USD | -518.2% |
| 2016 Q1 | -497.33 Thousand USD | 49.89% |
| 2016 Q2 | -2.18 Million USD | -339.56% |
| 2016 Q3 | -2.66 Million USD | -21.74% |
| 2016 Q4 | 1.72 Million USD | 164.94% |
| 2016 FY | -3.56 Million USD | -49.67% |
| 2015 Q3 | -373.09 Thousand USD | 50.05% |
| 2015 Q4 | -992.41 Thousand USD | -166.0% |
| 2015 Q2 | -746.91 Thousand USD | -178.72% |
| 2015 Q1 | -267.98 Thousand USD | -1277.59% |
| 2015 FY | -2.38 Million USD | -1057.82% |
| 2014 Q4 | -19.45 Thousand USD | 73.25% |
| 2014 Q2 | -112.95 Thousand USD | -41.49% |
| 2014 FY | -205.59 Thousand USD | 53.46% |
| 2014 Q1 | -79.83 Thousand USD | 72.21% |
| 2014 Q3 | -72.72 Thousand USD | 35.62% |
| 2013 Q3 | 4418.00 USD | 0.0% |
| 2013 Q1 | -158.86 Thousand USD | 0.0% |
| 2013 FY | -441.78 Thousand USD | 86.74% |
| 2013 Q4 | -287.32 Thousand USD | -6603.6% |
| 2013 Q2 | - USD | 100.0% |
| 2012 FY | -3.33 Million USD | -532.15% |
| 2011 FY | -527.13 Thousand USD | -121.23% |
| 2010 FY | -238.27 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -535.224% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -21.483% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 116.012% |
| Nascent Biotech, Inc. | -2.08 Million USD | -306.335% |
| Rebus Holdings, Inc. | -1.02 Million USD | -731.665% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 113.024% |
| Qrons Inc. | -789.34 Thousand USD | -974.684% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1241.38% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 86.449% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1941.736% |
| Skye Bioscience, Inc. | -37.64 Million USD | 77.466% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 88.684% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -28.997% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3002.751% |
| SQZ Biotechnologies Company | -79.46 Million USD | 89.325% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -193.286% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -365.963% |
| Mesoblast Limited | -87.95 Million USD | 90.355% |
| Marizyme, Inc. | -65.34 Million USD | 87.019% |
| Genus plc | 7.9 Million USD | 207.38% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 22.115% |
| Pharming Group N.V. | -10.54 Million USD | 19.577% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -290.954% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -128.637% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 4.082% |
| ContraFect Corporation | -65.15 Million USD | 86.98% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -73.616% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -391.068% |
| IMV Inc. | -36.48 Million USD | 76.75% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -5.252% |
| MultiCell Technologies, Inc. | -380.07 USD | -2231853.061% |
| ONE Bio Corp. | 8.67 Million USD | 197.768% |
| Accustem Sciences Inc. | -3.74 Million USD | -126.429% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 83.589% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -569.462% |
| Q BioMed Inc. | -2.05 Million USD | -313.382% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -127.243% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -256.298% |
| Biomind Labs Inc. | -1.21 Million USD | -598.58% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 85.797% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -173.489% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -7.338% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -335.192% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -56543.857% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 46.552% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -45.825% |
| GB Sciences, Inc. | -1.36 Million USD | -522.981% |
| Alpha Cognition Inc. | -13.77 Million USD | 38.407% |
| HST Global, Inc. | -146.21 Thousand USD | -5701.918% |
| CSL Limited | 2.64 Billion USD | 100.321% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -383.424% |
| Halberd Corporation | -79.67 Thousand USD | -10546.85% |
| Enzolytics Inc. | -2.17 Million USD | -289.694% |
| Agentix Corp. | -1.37 Million USD | -517.299% |
| Resverlogix Corp. | -3.61 Million USD | -134.986% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -167.481% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.125% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8756.106% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 222.505% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -113.516% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -180.324% |
| AVAX Technologies, Inc. | -6.41 Million USD | -32.265% |
| Zenith Capital Corp. | -10.59 Million USD | 19.942% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.115% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -36398.511% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -104.61% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -13935.239% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -323.067% |
| Kadimastem Ltd | -3.3 Million USD | -156.485% |
| Helix BioMedix, Inc. | -1.05 Million USD | -703.27% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -122.126% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1821.971% |
| LadRx Corporation | 400.44 Thousand USD | 2218.4% |
| Cell Source, Inc. | -5.32 Million USD | -59.418% |
| Regen BioPharma, Inc. | 1.02 Million USD | 928.815% |
| Regen BioPharma, Inc. | 1.02 Million USD | 928.815% |
| NovAccess Global Inc. | -4.76 Million USD | -77.871% |
| Affymax, Inc. | -14.42 Million USD | 41.188% |
| Itoco Inc. | -1.86 Million USD | -353.879% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -90.949% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -408.267% |
| Mobile Lads Corp. | -2.26 Million USD | -274.807% |
| CytoDyn Inc. | -49.84 Million USD | 82.98% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -10633.471% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3618.536% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -800.98% |
| SYBLEU INC | -180.3 Thousand USD | -4604.823% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -425.999% |
| International Stem Cell Corporation | -131 Thousand USD | -6375.56% |
| Bioxytran, Inc. | -4.28 Million USD | -98.2% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -15530.498% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -235.263% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 82.354% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -301.276% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -986.327% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -167.771% |
| Neutra Corp. | -233.46 Thousand USD | -3533.514% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 58.193% |
| PureTech Health plc | -65.69 Million USD | 87.088% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 60.111% |
| IXICO plc | -1.17 Million USD | -620.117% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 14.546% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 85.151% |
| CSL Limited | 2.64 Billion USD | 100.321% |
| Cellectis S.A. | -103.17 Million USD | 91.778% |